Table 2: The effect of selected agents on skeletal-related events (SREs) and pain palliation response based on randomized clinical trials.

AgentSRE (% incidence or time to SRE)Pain palliation response

Docetaxel versus mitoxantrone [8]NE35% versus 22% ( )
Abiraterone acetate versus placebo [12, 13]25.0 versus 20.3 months ( )45% versus 28.8% ( )
Enzalutamide versus placebo [11, 14]16.7 versus 13.3 months ( )NR
Cabazitaxel versus mitoxantrone [74]NE9.2% versus 7.7% ( )
Zoledronic acid versus placebo [5]33.2% versus 44.2% ( ), 14.9 months versus 10.7 months ( ) 7% bone pain index ( )
Denosumab versus zoledronic acid [16]20.7 versus 17.1 months ( )NE
Denosumab versus placebo (non-mCRPC) [44]29.5 versus 25.3 months ( )NE
Sm-153 versus placebo [18]NE72% pain relief ( )
Sr-89 [53]NEMean complete pain response 32%, mean partial pain response 44%
Ra 223 versus placebo [21]15.6 versus 9.8 months ( )NE
Cabozantinib [67]NE64% improvement

NE: not examined and NR: not reported.